RenovoRx (RNXT) investor relations material

Technology and clinical innovation

• Proprietary RenovoCath device delivers high concentrations of chemotherapy directly to hypovascular tumors, reducing systemic toxicity by 50% and increasing tissue drug concentration by 100 times compared to systemic delivery.

• The Trans-Arterial Micro-Perfusion (TAMP) mechanism enables targeted therapy for tumors with limited blood supply, such as pancreatic and bile duct cancers.

• Outpatient procedure with conscious sedation allows for easier patient experience and simpler physician training, requiring only a small proctoring team.

• Phase III TIGeR-PaC trial completed enrollment, with interim data showing a six-month survival benefit and 65% reduction in systemic toxicities.

• Investigator-initiated trials are expanding into borderline resectable and metastatic pancreatic cancer, as well as cholangiocarcinoma.

Commercial progress and market opportunity

• RenovoCath is FDA-cleared and commercially available in 21 centers, with expectations to exceed 35 centers by year-end and a pipeline of 63 centers in various stages of adoption.

• The addressable market for locally advanced pancreatic cancer is estimated at $400 million in peak annual sales, with expansion potential into other tumor types.

• Device commands $6,000–$8,500 per unit, with patients averaging six treatments, and the business operates at 85% gross margins and targets 30% operating margins.

• Lean sales force of 4–5 reps covers the concentrated U.S. market, focusing on 200 centers that treat the majority of relevant tumors.

• Commercial ramp is supported by transitioning phase III trial centers to commercial customers and ongoing post-market studies at major cancer centers.

Financial performance and outlook

• Q2 revenue reached a record $909,000, up 115% year-over-year and 61% quarter-over-quarter; first half revenue totaled $1.5 million, a 138% increase over the prior year.

• Revenue guidance for the year was raised to $3.75–$4.25 million, reflecting strong commercial momentum and center adoption.

• Targeting at least 36 active cancer centers by year-end, up from five the previous year, to drive continued revenue growth.

• Patent portfolio includes 20 issued and 13 pending patents, providing exclusivity through 2045.